Irbotens Plus (Hydrochlorothiazide, Irbesartan)

Hydrochlorothiazide / Irbesartan, the active ingredient in Irbotens Plus, is a Angiotensin II receptor blocker (ARB) and thiazide diuretic combination presented as an oral tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Irbotens Plus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbotens Plus is an antihypertensive medication that works within the renin‑angiotensin‑aldosterone system to lower blood pressure. Hypertension: reduces systolic and diastolic pressure and lowers cardiovascular risk. Essential hypertension: provides consistent blood‑pressure control when monotherapy is insufficient. Hypertension with fluid retention: adds diuretic effect to improve volume management.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Hyperkalemia - Angioedema or swelling of face, lips, tongue - Acute kidney injury - Severe hypotension - Allergic skin reactions such as Stevens‑Johnson syndrome

Irbotens Plus requires careful monitoring and patient education before and during therapy. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Electrolyte assessment: monitor potassium and sodium levels, especially in patients on other diuretics. - Renal function: evaluate creatinine and eGFR before initiation and periodically thereafter. - Use with caution in elderly patients due to increased risk of orthostatic hypotension. - Avoid in patients with severe hepatic impairment unless benefits outweigh risks. - Store at below 25°C: keep in the original pack, protect from moisture.

Irbotens Plus can interact with several medicines that affect blood pressure, electrolytes, or renal function. Major Interactions (Avoid): - Aliskiren: combined use may increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: can increase lithium levels and toxicity. - ACE inhibitors: concurrent use may raise risk of angioedema and renal dysfunction. - NSAIDs: may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may require dose adjustments to prevent hypotension. - Antidiabetic agents: blood‑glucose control may improve, risking hypoglycemia. - Digoxin: monitor serum levels as diuretic‑induced electrolyte changes can affect toxicity. - Corticosteroids: may increase sodium retention, counteracting diuretic effect. - Antimicrobials such as trimethoprim‑sulfamethoxazole: can raise potassium levels.